TW202540181A - 抗體-光敏感性物質複合體 - Google Patents

抗體-光敏感性物質複合體

Info

Publication number
TW202540181A
TW202540181A TW113144051A TW113144051A TW202540181A TW 202540181 A TW202540181 A TW 202540181A TW 113144051 A TW113144051 A TW 113144051A TW 113144051 A TW113144051 A TW 113144051A TW 202540181 A TW202540181 A TW 202540181A
Authority
TW
Taiwan
Prior art keywords
antibody
group
ch2ch2o
groups
alkyl group
Prior art date
Application number
TW113144051A
Other languages
English (en)
Chinese (zh)
Inventor
岩城竹彦
目黒正規
太田一平
扇谷祐輔
丹澤文惠
中村健介
米田耕三
伊東陽輝
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202540181A publication Critical patent/TW202540181A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW113144051A 2023-11-17 2024-11-15 抗體-光敏感性物質複合體 TW202540181A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-196281 2023-11-17
JP2023196281 2023-11-17

Publications (1)

Publication Number Publication Date
TW202540181A true TW202540181A (zh) 2025-10-16

Family

ID=95742828

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113144051A TW202540181A (zh) 2023-11-17 2024-11-15 抗體-光敏感性物質複合體

Country Status (3)

Country Link
JP (1) JPWO2025105486A1 (cg-RX-API-DMAC7.html)
TW (1) TW202540181A (cg-RX-API-DMAC7.html)
WO (1) WO2025105486A1 (cg-RX-API-DMAC7.html)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7943586B2 (en) * 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体
CN100567301C (zh) * 2007-10-23 2009-12-09 东华大学 一种叶绿素衍生物、其制备方法及在医农药领域的应用
EP2100621A1 (en) * 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2016052971A1 (ko) 2014-09-30 2016-04-07 가톨릭대학교 산학협력단 유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법
KR101656238B1 (ko) * 2014-12-03 2016-09-09 인제대학교 산학협력단 광역학 치료용 광민감제로 유용한 양이온성 클로린계 및 퍼퓨린이마이드계 화합물과 이들의 클로린계- 및 퍼퓨린이마이드계-다중금속산화물의 착화합물
US11559581B2 (en) 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
CN109462989A (zh) 2016-07-01 2019-03-12 第三共株式会社 Hanp-含fc分子缀合物
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
US12678512B2 (en) 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative

Also Published As

Publication number Publication date
WO2025105486A1 (ja) 2025-05-22
JPWO2025105486A1 (cg-RX-API-DMAC7.html) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7556073B2 (ja) 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
JP7627655B2 (ja) 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
AU2024336691A1 (en) Macrocyclic compound and antibody-drug conjugate thereof
TWI757740B (zh) 甘胺酸醯胺化合物及其製造方法
TW202102226A (zh) 抗體-吡咯并苯二氮呯衍生物結合物及parp抑制劑之組合
CN113166764B (zh) 抗cdh6抗体-吡咯并苯并二氮杂环庚三烯衍生物缀合物
JP2020512270A (ja) ピロロベンゾジアゼピン二量体前駆体及びそのリガンド−リンカーコンジュゲート化合物
KR20250150111A (ko) 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도
JP2024509099A (ja) 抗her2抗体‐薬物コンジュゲートおよびその使用
CA3232764A1 (en) Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
CN119095625A (zh) 抗体-药物偶联物
TW202444425A (zh) 抗ror1抗體與pbd類化合物的偶聯物、其製備方法及其應用
CN119156232A (zh) 抗体-药物偶联物前体及其合成中间体
WO2025105486A1 (ja) 抗体-光感受性物質コンジュゲート
HK40081719B (en) Preparation method for antibody medicament conjugate
HK40054688A (en) (anti-cdh6 antibody)-(pyrrolobenzodiazepine derivative) conjugate